High Redemptions on ZeroFox

by | May 4, 2022

LNFA approves extension for ZeroFox, high redemptions. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

LNFA extends, high redemptions

L&F Acquisition Corp. (LNFA) shareholders approve extension on merger with cybersecurity provider ZeroFox to August 24th. High redemptions: 13.M shares redeemed (78.1%).

PONO / Benuvia raises $50M convert

PONO Capital Corp. (PONO) target Benuvia announces $50M convertible offering. Benuvia is a drug developer focused on pharmaceutical cannabinoids. The company owns the FDA approved cannabinoid drug SYNDROS® and one of the largest synthetic cannabinoid manufacturing facilities in the U.S.

Deal terminated: GBRG / AgiiPlus

Goldenbridge Acquisition Corp. (GBRG) terminated its merger agreement with AgiiPlus. Shanghai-based AgiiPlus provides flexible office space and software solutions to businesses in China and Singapore. GBRG will look for another transaction, but has a transaction deadline coming up on June 4.

Elsewhere in SPACs

  • Boardroom Alpha April SPAC market review. Check out our SPAC market review for April. Quick take: a hawkish Fed and even more cautious SEC are slowing, downsizing, and cancelling deals.

Upcoming Events

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Daily SPAC Update – April 20, 2026

Piermont Announces Deal with Tigerless Health. Climaterock sets extension vote. Horizon Space Extension Vote Today. Suma, TRG Latin America, and MOZAYYX Separate Trading.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.